• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Remy Healthcare

Remy Healthcare

Infusion Suites & 340B Services

  • Healthcare Professionals
    • About Remy Healthcare
      • Our Team
      • Advisory Partners
    • Services
      • Infusion
      • Telemedicine
      • TPA Services for 340B Programs
  • Patients
    • Infusion
      • Infusions Treatments
      • FAQs
      • Resources
      • Find A Remy Infusion Site
    • Telemedicine
      • Telemedicine Treatments
  • Blog
  • Foundation
  • Contact

What Infusions Does Remy Healthcare Offer?

We’re proud to offer a full range of infusion options for common conditions like Asthma, Migraines, Osteoporosis, Iron Deficiency, Rheumatoid Arthritis, and Multiple Sclerosis.

Infusions for medical conditions:

  • Actemra – Tocilizumab
  • Apretude – Icatibant
  • Avsola – Infliximab-axxq
  • Benlysta – Belimumab
  • Bivigam 
  • Cinryze – C1 Esterase Inhibitor 
  • Cimzia – Certolizumab pegol
  • Dihydroergotamine (DHE) 
  • Entyvio – Vedolizumab
  • Evenity – Romosozumab
  • Fasenra – Benralizumab
  • Felbogamma dif 
  • Ferraheme – Ferumoxytol
  • Ferrlecit – Sodium Ferric Gluconate
  • Gammagard 
  • Gammaked-c 
  • Gamunex-c 
  • Glassia – Alpha-1-Proteinase Inhibitor
  • Injectafer – Ferric Carboxymaltose
  • Infed – Iron Dextran
  • Inflectra – Infliximab-dyyb
  • Krystexxa – Pegloticase
  • Lemtrada – Alemtuzumab
  • Nucala – Mepolizumab
  • Octagam 
  • Ocrevus – Ocrelizumab
  • Orencia – Abatacept
  • Privigen 
  • Prolastin-c – Alpha-1-Proteinase Inhibitor 
  • Prolia – Denosumab
  • Remicade – Infliximab
  • Renflexis – Infliximab-abda
  • Rituxan – Rituximab
  • Saphnelo – Anifrolumab-fnia
  • Simponi – Golimumab
  • Stelara – Ustekinumab
  • Truxima – Rituximab-abbs
  • Tysabri – Natalizumab
  • Venofer – Iron Sucrose
  • Xolair – Omalizumab
  • Zoledronic acid 

Footer

340B Portal | Careers | Privacy Policy

  • facebook-alt
  • instagram
  • linkedin

Copyright © 2025. Remy Healthcare. All rights reserved. Site by 21 Designs.